Sana Biotechnology (NASDAQ:SANA – Get Free Report) had its price objective dropped by equities research analysts at Citigroup to $11.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup‘s price target suggests a potential upside of 480.47% from the stock’s previous close.
Other equities research analysts have also issued reports about the stock. Weiss Ratings lowered shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday. Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, November 7th. TD Cowen upgraded shares of Sana Biotechnology to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Bank of America lowered their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.83.
Check Out Our Latest Stock Report on SANA
Sana Biotechnology Stock Down 6.2%
Shares of SANA stock traded down $0.12 on Monday, hitting $1.90. The stock had a trading volume of 2,464,938 shares, compared to its average volume of 3,167,266. Sana Biotechnology has a one year low of $1.86 and a one year high of $5.49. The business has a 50 day moving average price of $2.72 and a 200 day moving average price of $3.29. The company has a market cap of $567.81 million, a PE ratio of -3.58 and a beta of 2.30.
Sana Biotechnology (NASDAQ:SANA – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.01. Equities research analysts expect that Sana Biotechnology will post -0.57 EPS for the current year.
Institutional Trading of Sana Biotechnology
A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new position in Sana Biotechnology during the 2nd quarter valued at about $58,196,000. Canada Pension Plan Investment Board acquired a new stake in Sana Biotechnology during the second quarter valued at approximately $35,662,000. Bank of America Corp DE acquired a new position in shares of Sana Biotechnology in the 2nd quarter worth $20,062,000. Alphabet Inc. purchased a new stake in Sana Biotechnology during the second quarter valued at about $9,816,000. Finally, Deutsche Bank AG acquired a new position in Sana Biotechnology in the 2nd quarter worth approximately $2,251,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.
About Sana Biotechnology
Sana Biotechnology, Inc. is a clinical-stage biotechnology company founded in 2018 and headquartered in Seattle. It develops engineered cells intended to treat a range of diseases, including cancer, autoimmune disorders and conditions that may be addressed through cell replacement. The company’s research focuses on modifying cells to improve their therapeutic properties, including approaches designed to help transplanted cells evade immune rejection. Its programs include engineered immune-cell therapies and cell-replacement treatments, such as work involving insulin-producing cells for type 1 diabetes.
Recommended Stories
- Five stocks we like better than Sana Biotechnology
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
